Peger Biopharmaceutical-B (02565) announced interim results with R&D expenditure of 110 million yuan

According to the Zhitong Finance App, Peger Biopharmaceutical-B (02565) announced interim results for the six months ended June 30, 2025. The group achieved other net losses of RMB 11.27 million (same unit), R&D expenses of RMB 110 million, and loss of 0.55 yuan per share.

During the reporting period and up to the date of this announcement, the Group has made significant progress in commercialization of core products, promotion of innovative product pipelines, capacity building for next-generation intelligent R&D, and global cooperation.

The commercialization of the Group's core product vipenatide injection (PB-119, trade name: Pidacan®) continued to advance during the reporting period. In March 2026, the Group signed a strategic cooperation agreement with Shanghai Tengrui Pharmaceutical Co., Ltd. (Tenri Pharmaceutical) for commercialization of vipernatide injections in mainland China (this agreement), and received an initial equity payment of approximately HK$61.0 million from Tenri Pharmaceuticals under the agreement in June 2026. Vipenatide injections have been included in the “2026 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue and Commercial Insurance Innovative Drug Catalogue Adjustment and Declared Drugs List Passing Preliminary Form Review” issued by the National Medical Security Administration. It has already passed the “Extracurricular Condition 1” application conditions, and further progress has been made in the market entry process. After the reporting period, Pidacom® has successively issued the first batch of commercial prescriptions at various medical institutions to further promote the clinical application and patient accessibility of the product. With the successful issuance of the first batch of commercialized Patacom® prescriptions across the country, all conditions for the second installment of approximately HK$49 million stipulated in the agreement have been fulfilled. The Group expects to receive this amount within the payment period specified in the agreement.

While commercializing core products, the Group continues to focus on the fields of diabetes, obesity and related metabolic diseases to promote next-generation innovative therapies with potential for differentiation. During the reporting period, CR059 made phased progress in its first human research, and the relevant research results were accepted by important international academic conferences. The Group also continues to advance pre-clinical and follow-up development of key innovative candidate products such as APGP6 and PB-2312. The Group continuously and dynamically evaluates and optimizes the development priorities of each R&D project based on clinical value, product differentiation potential, market competition pattern and R&D resource allocation.